197 related articles for article (PubMed ID: 35715669)
1. Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.
Barshidi A; Karpisheh V; Noukabadi FK; Kiani FK; Mohammadi M; Afsharimanesh N; Ebrahimi F; Kiaie SH; Navashenaq JG; Hojjat-Farsangi M; Zolbanin NM; Mahmoodpoor A; Hassannia H; Nami S; Jalali P; Jafari R; Jadidi-Niaragh F
Pharm Res; 2022 Aug; 39(8):1851-1866. PubMed ID: 35715669
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.
Karoon Kiani F; Izadi S; Ansari Dezfouli E; Ebrahimi F; Mohammadi M; Chalajour H; Mortazavi Bulus M; Nasr Esfahani M; Karpisheh V; Mahmoud Salehi Khesht A; Abbaszadeh-Goudarzi K; Soleimani A; Gholizadeh Navashenaq J; Ahmadi M; Hassannia H; Hojjat-Farsangi M; Shahmohammadi Farid S; Hashemi V; Jadidi-Niaragh F
Life Sci; 2022 Jan; 288():120166. PubMed ID: 34813798
[TBL] [Abstract][Full Text] [Related]
3. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
4. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
[TBL] [Abstract][Full Text] [Related]
5. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
7. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy.
Masjedi A; Ahmadi A; Ghani S; Malakotikhah F; Nabi Afjadi M; Irandoust M; Karoon Kiani F; Heydarzadeh Asl S; Atyabi F; Hassannia H; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Nanomedicine; 2020 Oct; 29():102240. PubMed ID: 32553948
[TBL] [Abstract][Full Text] [Related]
8. Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine.
Esmaily M; Masjedi A; Hallaj S; Nabi Afjadi M; Malakotikhah F; Ghani S; Ahmadi A; Sojoodi M; Hassannia H; Atyabi F; Namdar A; Azizi G; Ghalamfarsa G; Jadidi-Niaragh F
J Control Release; 2020 Oct; 326():63-74. PubMed ID: 32580042
[TBL] [Abstract][Full Text] [Related]
9. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
[TBL] [Abstract][Full Text] [Related]
10. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice.
Ge Y; Xi H; Ju S; Zhang X
Cancer Lett; 2013 Aug; 336(2):253-9. PubMed ID: 23523609
[TBL] [Abstract][Full Text] [Related]
11. The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy.
Du H; Yi Z; Wang L; Li Z; Niu B; Ren G
Int Immunopharmacol; 2020 Jan; 78():106113. PubMed ID: 31841754
[TBL] [Abstract][Full Text] [Related]
12. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
13. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
[TBL] [Abstract][Full Text] [Related]
14. Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.
Kheshti AMS; Hajizadeh F; Barshidi A; Rashidi B; Ebrahimi F; Bahmanpour S; Karpisheh V; Noukabadi FK; Kiani FK; Hassannia H; Atyabi F; Kiaie SH; Kashanchi F; Navashenaq JG; Mohammadi H; Bagherifar R; Jafari R; Zolbanin NM; Jadidi-Niaragh F
Pharm Res; 2022 Feb; 39(2):353-367. PubMed ID: 35166995
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
16. miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
Zhang M; Shi Y; Zhang Y; Wang Y; Alotaibi F; Qiu L; Wang H; Peng S; Liu Y; Li Q; Gao D; Wang Z; Yuan K; Dou FF; Koropatnick J; Xiong J; Min W
Cancer Immunol Immunother; 2020 Jun; 69(6):951-967. PubMed ID: 32076794
[TBL] [Abstract][Full Text] [Related]
17. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.
Yazdani M; Gholizadeh Z; Nikpoor AR; Mohamadian Roshan N; Jaafari MR; Badiee A
Sci Rep; 2021 Jul; 11(1):14661. PubMed ID: 34282215
[TBL] [Abstract][Full Text] [Related]
19. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
[TBL] [Abstract][Full Text] [Related]
20. Shed it, and help-LAG3 cleavage drives conventional CD4
Seidel L; Bengsch B
Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
